share_log

T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.

T2 Biosystems | SC 13D: Statement of acquisition of beneficial ownership by individuals-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%), etc.

T2 Biosystems | SC 13D：超過5%持股股東披露文件-Nathan D. Hukill(46.68%),CR Group L.P.(46.68%)等
美股SEC公告 ·  2024/04/19 16:36

Moomoo AI 已提取核心訊息

On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
On April 12, 2024, a significant change in ownership was reported for T2 Biosystems, Inc., a company specializing in medical diagnostic technology. A group led by Nathan D. Hukill, including CR Group L.P. and various CRG Partners funds, filed a Schedule 13D with the SEC, indicating they had collectively acquired a 46.68% beneficial ownership in T2 Biosystems. This acquisition was the result of a debt cancellation agreement in exchange for common stock, which was previously reported in a Schedule 13G filing. The group's beneficial ownership crossed the 20% threshold, triggering the Schedule 13D filing requirement. The shares were acquired for investment purposes with the intention of increasing the value of their investment in T2 Biosystems. The group may consider acquiring additional shares or disposing of their holdings in the future. The principal business of the group is healthcare-focused investments, and they have not been involved in any legal proceedings related to securities laws in the past five years.
2024年4月12日，據報道，專門從事醫療診斷技術的公司T2 Biosystems, Inc. 的所有權發生了重大變化。由內森·哈基爾領導的一個集團，包括CR集團有限責任公司和CRG Partners的各種基金，向美國證券交易委員會提交了附表13D，表示他們共同收購了T2 Biosystems4％的受益所有權。此次收購是以普通股換取債務取消協議的結果，該協議此前已在附表13G的文件中進行了報告。該集團的實益所有權超過了20％的門檻，觸發了附表13D的申報要求。收購這些股票是出於投資目的，目的是增加他們對T2 Biosystems的投資價值。該集團將來可能會考慮收購更多股份或出售其持有的股份。該集團的主要業務是以醫療保健爲重點的投資，在過去五年中，他們沒有參與任何與證券法有關的法律訴訟。
2024年4月12日，據報道，專門從事醫療診斷技術的公司T2 Biosystems, Inc. 的所有權發生了重大變化。由內森·哈基爾領導的一個集團，包括CR集團有限責任公司和CRG Partners的各種基金，向美國證券交易委員會提交了附表13D，表示他們共同收購了T2 Biosystems4％的受益所有權。此次收購是以普通股換取債務取消協議的結果，該協議此前已在附表13G的文件中進行了報告。該集團的實益所有權超過了20％的門檻，觸發了附表13D的申報要求。收購這些股票是出於投資目的，目的是增加他們對T2 Biosystems的投資價值。該集團將來可能會考慮收購更多股份或出售其持有的股份。該集團的主要業務是以醫療保健爲重點的投資，在過去五年中，他們沒有參與任何與證券法有關的法律訴訟。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    特斯拉
    TSLA
    -- 355.840
    英偉達
    NVDA
    -- 138.850
    阿里巴巴
    BABA
    -- 124.730
    百度
    BIDU
    -- 97.480
    英特爾
    INTC
    -- 23.600
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啟，全球市場將如何演變？
    🎙️討論： 1. 關稅政策將如何影響美股、黃金、比特幣等核心資產的走勢？ 2. 在此背景下，有哪些投資機會值得關注？你會如何佈局？ 展开
    MicroStrategy 2024年第4季度業績電話會
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。